DYAI241220C2500
- 0.05
- -0.24-82.76%
Dyadic Newsroom
Dyadic International Receives $3M Grant to Develop Antibodies for RSV, Malaria
Express News | Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for Rsv and Malaria Using C1 Platform Technology
Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform Technology
Dyadic International, Inc. (DYAI) Q3 2024 Earnings Call Transcript Summary
Express News | HC Wainwright & Co. Reiterates Buy on Dyadic International, Maintains $6 Price Target
Dyadic International Reports Q3 2024 Growth and Strategic Advances
Dyadic Intl 3Q Rev $1.9M >DYAI
Dyadic | 10-Q: Q3 2024 Earnings Report
Express News | Dyadic International, Inc. Q3 EPS USD -0.01
Press Release: Dyadic Announces Third Quarter 2024 Financial Results and Strategic Progress Across Key Markets
Dyadic International Aligns CFO Incentives With Performance
Exploring Dyadic International's Earnings Expectations
Earnings Preview: Dyadic to Report Financial Results Post-market on November 12
Dyadic to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
Dyadic Expands Global Presence With Participation in Key Industry Events
Express News | Dyadic Provides Alternative Proteins Business Update and Announces Attendance at Bioprocess International Conference
Earnings Call: Dyadic International Focuses on Diverse Revenue Streams
Earnings Call Summary | Dyadic(DYAI.US) Q2 2024 Earnings Conference
Dyadic International, Inc. (DYAI) Q2 2024 Earnings Call Transcript
Dyadic | 10-Q: Q2 2024 Earnings Report